Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03650413 · ClinicalTrials.gov registry record · Phase 2
An Extension Study to Evaluate the Long-Term Safety and Tolerability of UTTR1147A in Participants With Moderate to Severe Ulcerative Colitis or Crohn's Disease
A Phase 2 study, sponsored by Genentech.
- Terminated
- Registry status
- Phase 2
- Development phase
- 143
- Enrollment target
NCT03650413 is a Phase 2 study that was terminated before completion, run by Genentech. The registered enrollment target is 143 participants.
The verdict
NCT03650413, a Phase 2 study, was terminated before completion, sponsored by Genentech.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 143 participants
- Enrollment target
Study Summary
This study will evaluate the long-term safety and tolerability of UTTR1147A in participants with moderate to severe ulcerative colitis (UC) or Crohn's disease (CD), enrolling up to 320 participants from the parent studies: Phase Ib Study GA29469 (NCT02749630) and Phase II Study GA39925 (NCT03558152).
Interventions
- DRUG UTTR1147A
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 143 participants |
| Start Date | 2019-01-14 |
| Est. Completion | 2022-07-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03650413
The ClinicalTrials.gov registry entry for NCT03650413 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 143 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Genentech, which has 332 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which UTTR1147A is the first listed.
NCT03650413 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03650413 about?
NCT03650413 is a clinical study titled "An Extension Study to Evaluate the Long-Term Safety and Tolerability of UTTR1147A in Participants With Moderate to Severe Ulcerative Colitis or Crohn's Disease". This study will evaluate the long-term safety and tolerability of UTTR1147A in participants with moderate to severe ulcerative colitis (UC) or Crohn's disease (CD), enrolling up to 320 participants from the parent studies: Phase Ib Study GA29469 (NCT02749630) and Phase II Study GA39925 (NCT03558152)...
What is the current status of trial NCT03650413?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 143 participants. The study started on 2019-01-14. Estimated completion is 2022-07-12.
What interventions are being tested in trial NCT03650413?
The interventions under investigation include: UTTR1147A (DRUG).
Who is sponsoring clinical trial NCT03650413?
This trial is sponsored by Genentech, which has 332 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.